Changrui Xiao, MD

Dr. Jeremiah P. Tao is a board-certified UCI Health ophthalmologist specializing in tear drainage problems, thyroid eye disease, eyelid drooping, eyelid malposition, orbital tumors and orbito-facial trauma. He also offers cosmetic procedures, including Botox® and fillers, laser resurfacing and eyelid, brow, midface and face lifts. Tao earned his medical degree from University of South Carolina School of Medicine in Columbia, where he also completed a residency in ophthalmology. Next, he completed a fellowship in ophthalmic plastic and reconstructive surgery at the Indiana University School of Medicine in Indianapolis. He is the UCI Health director of oculofacial plastic and orbital surgery and directs the School of Medicine’s prestigious oculoplastic surgery fellowship program, which is accredited by the American Society in Ophthalmic Plastic and Reconstructive Surgery. An active researcher, he also gives lectures around the world and serves on the editorial board of the journal Oculoplastic Surgery. He has been named a Physician of Excellence by the Orange County Medical Association for each of the last 10 years.

Dr. Tahseen Mozaffar is a board-certified UCI Health neurologist who specialize in neuromuscular disorders, including amyotrophic lateral sclerosis (ALS), myasthenia gravis, inflammatory myopathies, Pompe disease, muscle pathology and all types of muscular dystrophies. He serves as director of the UCI Health ALS & Neuromuscular Center, one of only six Muscular Dystrophy Association-designated centers in California. Mozaffar earned his medical degree at the Aga Khan University in Karachi, Pakistan, where he completed a rotating internship in internal medicine and general surgery. He completed a neurology residency at Barnes-Jewish Hospital in St. Louis, Mo., followed by a fellowship in neuromuscular disorders at Washington University, also in St. Louis. His research focus includes clinical and translational studies of neuromuscular disorders and he is the principal site investigator of more than a dozen clinical trials for myasthenia gravis, immune myopathies and rare and ultra-rare myopathies. He is also the lead UCI investigator for NeuroNEXT, a collaborative national effort to help streamline phase 2 clinical trials for brain disorders that is supported by the National Institute of Neurological Disorders and Stroke (NINDS). As an expert in rare and ultra-rare myopathies, he advises many pharmaceutical companies on clinical trial design and the identification of disease targets. He serves on a Pompe disease advisory board for Amicus Therapeutics and Spark Therapeutics, as well as on the data safety monitoring board for Acceleron and Sarepta Therapeutics. He also is a reviewer with the Emerging Technologies and Training in Neurosciences (ETTN) group for the National Institutes of Health (NIH). He has co-authored more than 175 peer-reviewed publications and has written or co-written more than a dozen book chapters and reviews. Mozaffar, who is also fluent in Hindi and Urdu.